News Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
74.54 ^USD	+3.00%		+15.10%	+4.08%

Apr. 22	Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating	MT
Apr. 22	Mizuho Raises Price Target on Intra-Cellular Therapies to $96 From $82, Keeps Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating	Apr. 22	MT
Mizuho Raises Price Target on Intra-Cellular Therapies to $96 From $82, Keeps Buy Rating	Apr. 22	MT
Intra-Cellular Therapies Prices Public Offering of Common Stock - April 18, 2024	Apr. 19	AQ
Intra-Cellular Therapies Prices $500 Million Stock Offering	Apr. 18	MT
Intra-Cellular Therapies Prices Public Offering of Common Stock	Apr. 17	AQ
Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating	Apr. 17	MT
BofA Securities Adjusts Price Target on Intra-Cellular Therapies to $91 From $82, Maintains Buy Rating	Apr. 17	MT
Baird Adjusts Price Target on Intra-Cellular Therapies to $103 From $83, Maintains Outperform Rating	Apr. 17	MT
TD Cowen Adjusts Price Target on Intra-Cellular Therapies to $90 From $80, Maintains Buy Rating	Apr. 17	MT
Morgan Stanley Lifts Price Target on Intra-Cellular Therapies to $92 From $85, Says Study 501 Exceeds Its Highest Expectations; Overweight Kept	Apr. 17	MT
Intra-Cellular Therapies Launches $500 Million Public Offering of Stock; Shares Edge Lower in Late Trade	Apr. 16	MT
UnitedHealth Group, Morgan Stanley rise; PNC Financial, Live Nation fall, Tuesday, 4/16/2024	Apr. 16	AQ
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock	Apr. 16	AQ
Sector Update: Health Care Stocks Higher Late Afternoon	Apr. 16	MT
Top Midday Gainers	Apr. 16	MT
US Stocks Lacking Direction Prior to Powell Remarks, Investors Looking for Signs of Future Rate Cuts by Federal Reserve	Apr. 16	MT
Intra-Cellular Therapies Stock Jumps After Major Depressive Disorder Treatment Study Shows Positive Results	Apr. 16	MT
Transcript : Intra-Cellular Therapies, Inc. - Special Call	Apr. 16
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder	Apr. 16	AQ
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder	Apr. 16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Intra-Cellular Therapies, Inc.

Equities

ITCI

US46116X1019

Summary

Filters